IM Cannabis

CIN assigns IM Cannabis Corp. an Underweight rating, with a composite near 30 and one-out-of-five conviction. The regulatory pillar leads in the low 50s, supported by an 80 enforcement subscore, a 50 jurisdiction posture, and filing cadence in the mid-30s. That relative strength is insufficient to offset fundamentals in the mid-20s, an editorial contribution around 30, and a market pillar in the mid-teens. Fundamentals reflect contracting sales, negative profitability, limited scale, and a stretched financial condition. The market score derives entirely from weak liquidity, while the editorial pillar reflects no recorded newsroom or brief activity in CIN newsroom coverage.

Licensed fundamentals data show year-over-year revenue contraction of approximately 31%, alongside a gross margin near 15% and an operating margin around negative 19%. Net income was a loss of roughly $13.9 million, while EBITDA was negative by about $6.4 million, confirming that operating performance remains loss-making. The cash-burn ratio exceeded 4.5, and the market capitalization was approximately $1.4 million, reinforcing constrained financial flexibility rather than balance-sheet resilience. Primary regulatory filings show one event during the latest 90-day period and two across 180 days, with the latest filing dated July 1, 2026. Institutional pricing feeds recorded no trading volume in the observed data, aligning with the 15 liquidity subscore and limiting dependable price discovery.

The clearest rerating catalyst sits within the regulatory pillar, already the company’s strongest contribution. A tighter sequence of primary regulatory filings, paired with preservation of the clean enforcement profile, delivers the most direct route to a higher composite because cadence remains materially below the enforcement subscore. Better disclosure frequency also enables investors to assess whether revenue contraction, negative margins, and elevated cash burn are stabilizing, while stronger filing activity can support broader CIN newsroom coverage. The single most important signal to watch is a sustained acceleration in primary regulatory filing cadence.